MAT2A-IN-21, identified by its CAS number 3062073-94-0, is a small molecule inhibitor that targets the enzyme methionine adenosyltransferase 2A (MAT2A). This enzyme plays a crucial role in the synthesis of S-adenosylmethionine (SAM), a key methyl donor in various biological processes, including methylation of DNA, RNA, and proteins. The inhibition of MAT2A can influence cellular metabolism and has potential implications in cancer research, as altered methionine metabolism is often associated with tumorigenesis. MAT2A-IN-21 is characterized by its specific binding affinity to the target enzyme, which can lead to a decrease in SAM levels, thereby affecting downstream methylation reactions. The compound's efficacy and selectivity are typically evaluated through biochemical assays and cellular models. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are essential for determining its potential therapeutic applications. Overall, MAT2A-IN-21 represents a promising avenue for research into metabolic regulation and cancer treatment strategies.

MAT2A-IN-21

3062073-94-0: MAT2A-IN-21, identified by its CAS number 3062073-94-0, is a small molecule inhibitor that targets the enzyme methionine adenosyltransferase 2A (MAT2A). This enzyme plays a crucial role in the synthesis of S-adenosylmethionine (SAM), a key methyl donor in various biological processes, including methylation of DNA, RNA, and proteins. The inhibition of MAT2A can influence cellular metabolism and has potential implications in cancer research, as altered methionine metabolism is often associated with tumorigenesis. MAT2A-IN-21 is characterized by its specific binding affinity to the target enzyme, which can lead to a decrease in SAM levels, thereby affecting downstream methylation reactions. The compound's efficacy and selectivity are typically evaluated through biochemical assays and cellular models. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are essential for determining its potential therapeutic applications. Overall, MAT2A-IN-21 represents a promising avenue for research into metabolic regulation and cancer treatment strategies.

<p>MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.</p>

CAS 3062073-94-0

MAT2A-IN-21

MAT2A-IN-21

Ref: TM-T204570